Annals of surgery
-
To review the literature evaluating the effect of practice guidelines and decision aids on use of surgery and regional variation. ⋯ Both practice guidelines and decision aids have been proven effective in many clinical contexts. Expanding the clinical scope of these tools and eliminating barriers to implementation will be essential to further efforts directed toward reducing regional variation in the use of surgery.
-
To perform a systematic review of interventions used to reduce adverse events in surgery. ⋯ Only a small cohort of medium- to high-quality interventions effectively reduce surgical harm and are feasible to implement. It is important that future research remains focused on demonstrating a measurable reduction in adverse events from patient safety initiatives.
-
Observational Study
Survivors versus nonsurvivors postburn: differences in inflammatory and hypermetabolic trajectories.
To evaluate whether a panel of common biomedical markers can be utilized as trajectories to determine survival in pediatric burn patients. ⋯ Nonsurvivors have different trajectories in inflammatory, metabolic, and acute phase responses allowing differentiation of nonsurvivors from survivors and now possibly allowing novel predictive models to improve and personalize burn outcomes.
-
To evaluate the ability of epithelial-to-mesenchymal transition-related microRNAs (miRNAs) as serum biomarkers for prognosis and prediction of metastasis in patients with colorectal cancer (CRC). ⋯ Serum miR-200c has strong potential to serve as a noninvasive biomarker for CRC prognosis and predicting metastasis.
-
To determine the efficacy of oral supplementation of the gut enzyme intestinal alkaline phosphatase (IAP) in preventing antibiotic-associated infections from Salmonella enterica serovar Typhimurium (S. Typhimurium) and Clostridium difficile. ⋯ Oral IAP supplementation protected mice from antibiotic-associated bacterial infections. We postulate that oral IAP supplementation could represent a novel therapy to protect against antibiotic-associated diarrhea (AAD), C. difficile-associated disease (CDAD), and other enteric infections in humans.